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The fragile X protein has many interactions
Since the discovery of the fragile X mental retardation 1 
(FMR1) gene in 1991, our knowledge of the molecular 
mechanisms  underlying  fragile  X  syndrome  (FXS)  has 
increased  tremendously  [1].  The  disorder  is  caused  by 
dynamic mutation of a single trinucleotide sequence, CGG, 
on the X chromosome. In patients, CGG repeat expan­
sion  and  subsequent  methylation  silences  the  FMR1 
gene,  preventing  transcription  of  the  fragile  X  mental 
retardation protein (FMRP).
FMRP is an RNA binding protein involved in mRNA 
transport  and  stability  and  also  in  local  protein  trans­
lation. The protein is estimated to interact with 4% of all 
brain mRNAs and with an unknown number of proteins 
in  the  mammalian  brain.  Absence  of  FMRP  leads  to 
perturbation  of  the  normal  cellular  function  of  many 
mRNAs and proteins. The resulting fragile X phenotype 
is characterized by intellectual disability, specific physical 
abnormalities, behavioral problems and epileptic seizures. 
Currently, there is no specific treatment for the disorder. 
Elucidating the pathophysiology of FXS is therefore not 
only important for the identification of potential thera­
peutic  targets,  but  could  also  provide  further  insights 
into the general mechanisms of cognition and behavior.
Various techniques have been used to determine the 
mRNA targets of FMRP, including co­immuno  preci  pi  ta­
tion followed by microarray analysis, antibody­positioned 
RNA  amplification  (APRA)  and,  most  recently,  high­
throughput sequencing of RNAs isolated by crosslinking 
immunoprecipitation (HITS­CLIP) [2]. Each study identi­
fied a large number of mRNA targets, encoding proteins 
involved in synaptic signaling pathways, such as gluta­
mate  and  γ­aminobutyric  acid  (GABA),  in  addition  to 
proteins involved in many other intracellular pathways. 
Proteomic  analysis  of  murine  hippocampal  synapses 
revealed abnormalities due to loss of translational regu­
lation  of  FMRP  [3].  Altered  expression  profiles  were 
found predominantly for proteins in specific functional 
groups,  such  as  synaptic  structure  and  cytoskeleton 
organi  zation, neurotransmission and metabolism.
A  recent  study  by  Davidovic  and  colleagues  [4], 
published in Genome Research, provides a new dimension 
to fragile X research by analyzing the brain metabolome 
of  Fmr1­deficient  mice.  By  combining  metabonomics 
data with results from previously published studies and 
with the knowledge of signaling and metabolic pathways 
gathered from databases, this work significantly increases 
our insight into the aberrant signaling pathways in FXS.
Metabonomics as a tool to study genetic disorders
Metabonomics  measures  the  dynamic  multiparametric 
metabolic  response  of  living  systems  to  pathological 
stimuli or genetic modification [5]. The collection of all 
metabolites (the intermediate and end products of cellular 
processes) in a biological sample is represented by the 
metabolome, which can reflect the ultimate response of 
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[6]. Metabonomics is a rapidly developing field with many 
potential  applications  in  cancer  and  neuro  degenera  tive 
disease  diagnostics,  monitoring  of  disease  progression, 
evalua  tion  of  drug  toxicity  and  development  of  thera­
peutics [7]. It can also be used to identify the underlying 
pathways involved in a disease.
Traditionally,  genomics  and  proteomics  approaches 
have been used to study the effect of genetic disorders. 
However, finding the relationship between altered gene 
or protein expression and the biological consequences is 
not always straightforward [5], especially given that the 
effect of a single genetic variation is often not limited to 
one biochemical pathway [6]. Metabonomics can help to 
identify the metabolites of seemingly unrelated bio  chemical 
pathways, and therefore might reveal potential new sites 
for  therapeutic  intervention.  The  metabolites  can  be 
detected by approaches based on mass spectro  metry or 
nuclear magnetic resonance (NMR) spectros  copy. In their 
study,  Davidovic  et  al.  [4]  used  solid  state  NMR, 
specifically 1H magic­angle­spinning NMR (1H HR­MAS 
NMR) spectroscopy. This method has the advan  tage of 
being  able  to  analyze  small  amounts  of  intact  tissues, 
unlike other methods, which require meta  bolites to be in 
solution. The technique can thus be used even if further 
analysis of the tissue sample is required.
Defects in key metabolic pathways
The  outcome  of  the  metabonomic  analysis  showed  25 
metabolites with altered concentrations in the fragile X 
Figure 1. Metabolic phenotype of Fmr1-deficient brain regions. The metabolites found to be downregulated (down-arrows in the left columns) 
or upregulated (up-arrows in the right columns) in Fmr1 knockout mice compared with wild-type mice are shown for each brain region. Co, cortex; 
st, striatum; ce, cerebellum; hi, hippocampus.
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Page 2 of 4brain (Figure 1). These 25 metabolites could be grouped 
into a small number of affected pathways, involved in one 
of  four  categories:  neurotransmission,  osmoregulation, 
energy metabolism and oxidative stress response. Some 
alterations are in line with reported anomalies in FXS, 
including  abnormalities  in  the  glutamatergic  and  the 
GABAergic pathways [1]. For instance, a reduced amount 
of GABA in the cortex and cerebellum is compatible with 
earlier reports of a compromised GABAergic system in 
the disorder. Increased glutamatergic signaling is another 
hallmark of the disorder [8]. It can be hypothesized that 
the  reduced  amount  of  free  glutamate  observed  by 
Davidovic et al. [4] is a protective reaction of the organ­
ism to the overstimulation of the group I metabotropic 
glutamate (mGluR) receptors. There have been isolated 
reports that the cholinergic system, a second inhibitory 
system in brain, is also involved in the disorder, mainly 
on the basis of results from fly studies [9]. The Davidovic 
et al. study [4] clearly shows that several components in 
the cholinergic pathway are compromised in the mouse 
model. This adds further evidence to the hypothesis that 
FXS is a consequence of the disturbance of the delicate 
balance  between  excitatory  and  inhibitory  signaling  in 
the brain.
To  integrate  the  abnormal  metabolite  concentrations 
with the data available from previous studies, the authors 
[4] developed a novel integrated metabolome and inter­
actome mapping (iMIM) approach. This systems biology 
approach was considered necessary because FMRP does 
not interact directly with the metabolites themselves and 
therefore cannot directly influence their concentrations. 
All  the  25  metabolites  were  linked  to  FMRP  in  the 
network  by,  on  average,  just  over  three  intermediate 
proteins. The distance within the network represents the 
mechanistic  link  between  FMRP  and  each  metabolite. 
Within the interaction network, only 12 mRNAs and one 
protein are linked directly to FMRP. Of these, some are 
known  interactors,  including  the  paralogous  protein 
FXR2P  and  mRNAs  encoding  subunits  of  the  GABAA 
receptor.  Interestingly,  a  key  interactor  is  the  amyloid 
beta precursor protein (APP) mRNA, which is implicated 
in Alzheimer’s disease. A previous study indicated that 
FMRP binds APP mRNA, but it is striking that APP is 
predicted to be in the center of the metabolite network, 
implying  a  pivotal  role.  Further  studies  are  needed  to 
evaluate the role of APP in FXS.
Another key interactor of FMRP emerging from this 
study  is  RhoA  mRNA.  RhoA  is  a  member  of  the  Rho 
GTPase family, and different members of this gene family 
have opposite roles in neurite outgrowth and retraction. 
Although it was known that the Rho GTPase Rac1, which 
promotes  neural  spine  formation,  was  involved  in  the 
disorder,  this  study  supports  the  involvement  of  the 
RhoA signaling pathway, which induces spine retraction. 
In line with this, expression of Larg, encoding a protein 
that activates RhoA, was reported to be compromised in 
FXS in an earlier study [10]. These findings emphasize 
the involvement of Rho GTPases in the neuro­anatomical 
pathophysiology of FXS, more specifically in the aberrant 
spine morphology associated with the disease.
The fragile X syndrome profile overlaps with that 
of other neurological disorders
This story [4] adds another layer of understanding to the 
complex phenotype of FXS and it contains both good and 
bad news for the design of drugs to treat the disorder. 
Although  it  confirms  a  key  role  of  inhibitory  and 
excitatory pathways, the abnormalities in these and other 
affected systems seem to be specific to particular brain 
regions and thus may require much more sophisticated 
drug  treatments  than  currently  anticipated  [1].  In 
addition, the abnormalities were detected in very young 
animals  and  an  effect  of  brain  development  on  the 
disturbances  of  metabolite  concentrations  cannot  be 
excluded. Further studies on mice in different age groups 
are necessary to clarify this issue.
The study from Davidovic and colleagues [4] highlights 
many similarities between the metabolome of FXS and 
that  of  other  neurological  disorders.  Examples  include 
the neurodevelopmental disorder Rett syndrome and the 
neurodegenerative disorders Batten disease and Hunting­
ton’s disease, which have been analyzed by other groups 
using  metabonomics  [7].  Alterations  in  the  balance 
between the excitatory (glutamate) and inhibitory (GABA) 
neurotransmitters,  osmoregulation  (myo­inositol),  lipid 
metabolism (choline) and energy metabolism (creatine) 
were  the  most  commonly  observed  metabolic  changes 
across all these diseases. Thus, collectively these findings 
contribute  to  our  understanding  of  the  mecha  nisms 
underlying neurological disorders in general.
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